1. The efficacy of imatinib in chronic phase chronic myeloid leukemia (CML) persisted after 10-year follow-up.
2. No new significant adverse events related to imatinib treatment were found after long-term follow-up.
Evidence Rating Level: 1 (Excellent)
Study Rundown: The 2003 IRIS trial (International Randomized study of Interferon and STI571) established imatinib as...
1. Mutations in the colony-stimulating factor 3 receptor (CSF3R) gene were found in a majority of samples of neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (CML).
2. Different types of CSF3R mutations are associated with vulnerability to different therapeutics in vitro and potentially in vivo.
Study Rundown: Aberrant kinases...